Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Leah Ansell

Dermatology New York, NY Medical Doctor

NPI 1114260429 CMS profile 3815321

1035 5Th Ave, New York, NY 10028

Open in the dashboard

General payments

$5,559

261 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leah Ansell of New York, NY is reported in the CMS Open Payments database as having received $5,559 across 261 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,824 80
2024 General $1,489 69
2023 General $914 46
2022 General $334 14
2021 General $203 8
2020 General $198 9
2019 General $597 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leah Ansell
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Leah Ansell were reported at $1,824. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Leah Ansell Dermatology median Middle half National median
2019 $597 $454 $129–$1,240 $163
2020 $198 $235 $81–$756 $114
2021 $203 $377 $108–$1,108 $132
2022 $334 $514 $143–$1,391 $149
2023 $914 $607 $159–$1,674 $160
2024 $1,489 $751 $204–$1,903 $164
2025 $1,824 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $1,057 55 payments
  2. AbbVie, Inc. $621 35 payments
  3. Galderma Laboratories, L.P. $465 19 payments
  4. Lilly USA, LLC $449 21 payments
  5. Regeneron Healthcare Solutions, Inc. $313 11 payments
  6. Merz North America, Inc. $281 7 payments
  7. Sun Pharmaceutical Industries Inc. $266 16 payments
  8. LEO Pharma Inc. $263 12 payments
  9. Pfizer Inc. $237 10 payments
  10. Incyte Corporation $233 12 payments
  11. Other $1,374 63 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,559 261 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $1,057 55 payments
  2. RINVOQ $308 16 payments
  3. TALTZ $248 12 payments
  4. Winlevi $237 14 payments
  5. OPZELURA $233 12 payments
  6. SOTYKTU $232 10 payments
  7. CIBINQO $213 8 payments
  8. DUPIXENT $207 7 payments
  9. EBGLYSS $202 9 payments
  10. SKYRIZI $189 13 payments
  11. Other $3,347 144 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

484

Median for Dermatology: 534

Drug cost

$149,298

Median for Dermatology: $67,151

Branded share of claims

9.7%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Taltz Autoinjector Ixekizumab Brand 12 $83,236
Dupixent Syringe Dupilumab Brand 14 $53,522
Fluorouracil Generic 81 $6,335
Clobetasol Propionate Generic 40 $1,719
Metronidazole Generic 13 $912
Triamcinolone Acetonide Generic 76 $854
Fluocinonide Generic 11 $583
Minoxidil Generic 91 $432
Ketoconazole Generic 37 $404
Valacyclovir Valacyclovir Hcl Brand 21 $355

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$138,709

Of which drugs: $38

Medicare patients

506

Average age 76

Services billed

2,595

355 women, 151 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 51%
Arthritis 42%
Osteoporosis 30%
Ischemic heart disease 19%
Cancer 19%
Diabetes 13%
Atrial fibrillation 13%
Depression 10%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 14 21 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $411
$411 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $159
$159 — —
TALTZ
  • Lilly USA, LLC $118
$118 12 —
RINVOQ
  • AbbVie, Inc. $101
$101 — —
ADBRY
  • LEO Pharma Inc. $91
$91 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

261 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record